Pharmac to extend growth-hormone aid for Prader-Willi

The Government's drug-funding agency, Pharmac, is expected to loosen its purse-strings to allow children with Prader-Labhart-Willi Syndrome access to subsidised growth-hormone treatments.

The syndrome is a genetic disorder that causes feelings of constant hunger. This means children want to eat nonstop and can become morbidly obese at a very young age. At the same time, it leaves them with limp muscles that make exercise exhausting.

A project manager at Pharmac, Jan Quin, has told some parents of Prader-Willi children they may qualify for subsidies for children who are very short or have growth-hormone deficiency. Until now the subsidy criteria usually rejected Prader-Willi children as "too tall".

European research in 1998 showed that Prader-Willi patients treated with human growth hormone not only reduced body fat but increased muscle mass and their capacity for exercise.

British authorities recommended growth hormone treatment for Prader-Willi Syndrome in 2002.

At least half a dozen New Zealand families have been paying $10,000 to $20,000 a year to provide the hormone treatment to their Prader-Willi children without subsidies.

The Prader-Willi Syndrome Association last year argued in a petition to Parliament - signed by 10,212 people - that all Prader-Willi children should be eligible for the internationally proven treatment.

Association head Linda Thornton - who presented the petition - has estimated the subsidies will cost the Government about $250,000 a year.

But Ms Quin said the subsidies, proposed to start from October 1, would have strict criteria.

Comments on the proposed criteria for funding close on Thursday.


Get the news delivered straight to your inbox

Receive the day’s news, sport and entertainment in our daily email newsletter


© Copyright 2017, NZME. Publishing Limited

Assembled by: (static) on production bpcf02 at 27 May 2017 23:06:46 Processing Time: 538ms